Filing Flows › 8-K events › Processa Pharmaceuticals

Processa Pharmaceuticals: other events

Form 8-K filed Oct 29, 2026 · items 8.01

FDA decisionsProcessa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics

What the filing says

Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria ; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosis

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Processa Pharmaceuticals’s other material 8-Ks

• Nov 4, 2026 — FDA decisions Processa Pharmaceuticals Announces Key Leadership Appointments

Other recent fda decisions

• Biovie Nov 6, 2026
• Acrivon Therapeutics Nov 6, 2026
• Entera Bio Nov 6, 2026
• Precision Biosciences Nov 5, 2026
• Sintx Technologies Nov 5, 2026
• Microbot Medical Nov 5, 2026
• Bioxytran Nov 5, 2026
• Palvella Therapeutics Nov 5, 2026
• ANI Pharmaceuticals Nov 5, 2026
• Teleflex Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.